G1 Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

G1 Therapeutics

01/03/2023 14:31

* G1 Therapeutics Inc  GTHX.OQ  reported a quarterly
adjusted loss
of 73 cents​​ per share for the quarter ended in December. The
mean expectation of eight analysts for the quarter was for a
loss of 84 cents per share.
    * Revenue rose 76.8% to $10.25 million from a year ago;
analysts
expected $9.66 million. 
    * G1 Therapeutics Inc's reported EPS for the quarter was a
loss
of 73 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.5%
in the last three months.​ 
    * In the last 30 days three analysts negatively revised
earnings
estimates 
    * G1 Therapeutics Inc shares had fallen by 33.3% this
quarter.
    * The company reported a quarterly loss of $33.65 million.
    * Wall Street's median 12-month price target for G1
Therapeutics
Inc is $14.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 1
at 02:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.84          -0.73          Beat
 Sep. 30 2022      -0.63          -0.59          Beat
 Jun. 30 2022      -1.02          -0.92          Beat
 Mar. 31 2022      -0.97          -1.15          Missed